×
About 28,932 results

ALLMedicine™ Metastatic Breast Cancer Center

Research & Reviews  12,633 results

A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients wit...
https://doi.org/10.1158/1078-0432.CCR-21-0047
Clinical Cancer Research : an Official Journal of the Ame... Jhaveri K, Drago JZ et. al.

May 5th, 2021 - Activating mutations in PIK3CA promote resistance to HER2-targeted therapy in breast cancer, however inhibition of PI3K alone leads to escape via feedback upregulation of HER3. Combined inhibition of HER2, HER3 and PI3K overcomes this mechanism pr...

Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and...
https://doi.org/10.1200/JCO.20.02822
Journal of Clinical Oncology : Official Journal of the Am... Lin NU, Pegram M et. al.

May 4th, 2021 - Effective therapies are needed for the treatment of patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) with brain metastases. A trastuzumab radioisotope has been shown to localize in brain metasta...

mTORC1 Inhibition in Metastatic Breast Cancer Patients Negatively Affects Peripheral NK...
https://doi.org/10.4049/jimmunol.2001215
Journal of Immunology (Baltimore, Md. : 1950); Besson L, Mery B et. al.

May 1st, 2021 - NK cells are cytotoxic lymphocytes displaying strong antimetastatic activity. Mouse models and in vitro studies suggest a prominent role of the mechanistic target of rapamycin (mTOR) kinase in the control of NK cell homeostasis and antitumor funct...

99mTc-HDP bone scintigraphy confirming parathyroid hormone-related peptide paraneoplast...
https://doi.org/10.1016/S1470-2045(21)00133-9
The Lancet. Oncology; Braat AJAT, Heerma van Voss MR et. al.

May 1st, 2021 - 99mTc-HDP bone scintigraphy confirming parathyroid hormone-related peptide paraneoplastic syndrome in metastatic breast cancer.|2021|Braat AJAT,Heerma van Voss MR,Bijlsma RM,|

Embolia Cutis Medicamentosa (Nicolau Syndrome) Secondary to Intramuscular Fulvestrant I...
https://doi.org/10.1177/08971900211012263
Journal of Pharmacy Practice; Murdock JL, Duco MR et. al.

Apr 29th, 2021 - A case of embolia cutis medicamentosa (Nicolau syndrome) in a patient receiving monthly intramuscular fulvestrant injections is presented. An 85-year-old woman receiving monthly fulvestrant injections in the outpatient setting developed a necrotic...

see more →

Guidelines  195 results

ESMO Guideline for Cancer Patient Management During the COVID-19 Pandemic
https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic?hit=ehp

Sep 17th, 2020 - These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients. The situation is evolving, and pragmatic ...

Differential risk of incident cancer in patients with heart failure: A nationwide population-based cohort study
https://www.journal-of-cardiology.com/article/S0914-5087(20)30271-9/fulltext
Journal of Cardiology; Kwak S

Aug 25th, 2020 - Patients with heart failure (HF) are more at risk of developing cancer than the general population.

ECOG-ACRIN Trial Reassures Clinicians, Patients That Locoregional Therapy Is Not Beneficial for Stage IV Metastatic Breast Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200218/full/

Jun 23rd, 2020 - For patients with stage IV metastatic breast cancer and an intact primary tumor (ITP), the early initiation of locoregional treatment (LRT) was not associated with longer survival or improvements in health-related quality of life (HRQoL) compared ...

see more →

Drugs  401 results see all →

Clinicaltrials.gov  14,451 results

A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients wit...
https://doi.org/10.1158/1078-0432.CCR-21-0047
Clinical Cancer Research : an Official Journal of the Ame... Jhaveri K, Drago JZ et. al.

May 5th, 2021 - Activating mutations in PIK3CA promote resistance to HER2-targeted therapy in breast cancer, however inhibition of PI3K alone leads to escape via feedback upregulation of HER3. Combined inhibition of HER2, HER3 and PI3K overcomes this mechanism pr...

Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and...
https://doi.org/10.1200/JCO.20.02822
Journal of Clinical Oncology : Official Journal of the Am... Lin NU, Pegram M et. al.

May 4th, 2021 - Effective therapies are needed for the treatment of patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) with brain metastases. A trastuzumab radioisotope has been shown to localize in brain metasta...

mTORC1 Inhibition in Metastatic Breast Cancer Patients Negatively Affects Peripheral NK...
https://doi.org/10.4049/jimmunol.2001215
Journal of Immunology (Baltimore, Md. : 1950); Besson L, Mery B et. al.

May 1st, 2021 - NK cells are cytotoxic lymphocytes displaying strong antimetastatic activity. Mouse models and in vitro studies suggest a prominent role of the mechanistic target of rapamycin (mTOR) kinase in the control of NK cell homeostasis and antitumor funct...

99mTc-HDP bone scintigraphy confirming parathyroid hormone-related peptide paraneoplast...
https://doi.org/10.1016/S1470-2045(21)00133-9
The Lancet. Oncology; Braat AJAT, Heerma van Voss MR et. al.

May 1st, 2021 - 99mTc-HDP bone scintigraphy confirming parathyroid hormone-related peptide paraneoplastic syndrome in metastatic breast cancer.|2021|Braat AJAT,Heerma van Voss MR,Bijlsma RM,|

Embolia Cutis Medicamentosa (Nicolau Syndrome) Secondary to Intramuscular Fulvestrant I...
https://doi.org/10.1177/08971900211012263
Journal of Pharmacy Practice; Murdock JL, Duco MR et. al.

Apr 29th, 2021 - A case of embolia cutis medicamentosa (Nicolau syndrome) in a patient receiving monthly intramuscular fulvestrant injections is presented. An 85-year-old woman receiving monthly fulvestrant injections in the outpatient setting developed a necrotic...

see more →

News  1,223 results

NICE Draft Guidance on New Treatment Option for Advanced Breast Cancer
https://www.medscape.com/viewarticle/949716

Apr 21st, 2021 - The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) as an option for treating HER2-positive unresectable or metastatic breast cancer i...

How Has COVID-19 Affected Metastatic Breast Cancer Treatment Decisions?
https://www.medscape.com/viewarticle/946340

Feb 25th, 2021 - Patients with metastatic breast cancer (MBC) face an elevated risk of severe illness or dying from COVID-19. Given the slow rollout of the Moderna and Pfizer COVID vaccines and new, more infectious viral variants circulating in the United States, ...

Obesity 'Clearly' Not Tied to Worse Survival in MBC
https://www.medscape.com/viewarticle/944913

Jan 28th, 2021 - The relationship between obesity and overweight and breast cancer has some elements of mystery. But this is not one of them: in metastatic breast cancer (MBC), excess body weight does not negatively influence outcomes. Multiple small studies have ...

Margetuximab for HER2+ Metastatic Breast Cancer Falls Short
https://www.medscape.com/viewarticle/943233

Jan 6th, 2021 - This transcript has been edited for clarity. Happy holidays, everyone. This is Dr Kathy Miller from Indiana University. I want to make sure you've had a chance to think carefully about the margetuximab approval by the US Food and Drug Administrati...

CONTESSA: Oral Taxane Meets Primary Endpoint
https://www.medscape.com/viewarticle/943090

Jan 5th, 2021 - This transcript has been edited for clarity. Hi. It's Dr Kathy Miller with more exciting news from the San Antonio Breast Cancer Symposium. I'm talking about the use of oral taxane therapy. You all know that the taxanes are a mainstay of our treat...

see more →

Patient Education  29 results see all →